HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A retrospective evaluation of nifedipine therapy in Prinzmetal's angina.

Abstract
A retrosepctive evaluation has been made of blood pressure, pulse rate, and number of anginal attacks per day in twenty-one patients diagnosed as Prinzmetal's Angina and treated with the investigational drug nifedipine. The effect of combining nifedipine with short- and long-acting nitrates or with propranolol was also evaluated. In consideration of the statisically significant reduction in the number of anginal attacks per day, p less than 0.001, together with the non-significant mean changes in blood pressure and pulse rate as well as the compatibility with the other drugs, it is concluded that nifedipine is a very useful drug, in a dose range of 30--120 mg per day, for the treatment of Prinzmetal's Angina. Recorded side-effects were of minimal severity and in no case caused nifedipine therapy to be discontinued.
AuthorsR Battye, C M Ordille
JournalThe Journal of international medical research (J Int Med Res) Vol. 7 Issue 5 Pg. 360-9 ( 1979) ISSN: 0300-0605 [Print] England
PMID499644 (Publication Type: Journal Article)
Chemical References
  • Pyridines
  • Vasodilator Agents
  • Nifedipine
Topics
  • Adult
  • Angina Pectoris (drug therapy)
  • Angina Pectoris, Variant (drug therapy)
  • Blood Pressure (drug effects)
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nifedipine (therapeutic use)
  • Pulse (drug effects)
  • Pyridines (therapeutic use)
  • Retrospective Studies
  • Vasodilator Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: